EchoStar Corporation Common Stock vs Twist Bioscience Corp — how do they compare? EchoStar Corporation Common Stock trades at $95.25 (market cap $28.41B), while Twist Bioscience Corp trades at $156.8 (market cap $10.32B). The key difference: EchoStar Corporation Common Stock is far larger — about 2.8× Twist Bioscience Corp's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, EchoStar Corporation Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 0 Days and Twist Bioscience Corp for 27 Days on average.
| ECHO | TWST | |
|---|---|---|
Market Cap | $28.41B | $10.32B |
Volume | 3,258,295 | 5,894,998 |
Sector | Media | Health |
52-Week High | $141.80 | $205.00 |
52-Week Low | $66.93 | $25.45 |
Typical Hold Time | 0 Days | 27 Days |
Enterprise Value | $45.47B | $10.24B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TWST trades at $152.05, down 8.94% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $376.57 million in 2025, but profitability remains elusive with a net income margin of -31.66%. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, providing a potential growth catalyst amid ongoing losses.
The outlook is mixed; analyst consensus is bullish with a $145.20 price target, but persistent losses and high valuation ratios pose significant risks. Investment opportunity hinges on the company's ability to monetize its AI collaborations and achieve profitability, while downside risks include cash burn and competitive pressures in the biotech sector.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →